-

Hologic to Announce Financial Results for the First Quarter of Fiscal 2022 on Wednesday, February 2, 2022

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2022 on Wednesday, February 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Interested participants may listen to the call by dialing 800-289-0720 (in the United States and Canada) or +1 323-701-0160 (for international callers) and referencing access code 1667821. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. A replay will be available approximately two hours after the call ends through Friday, February 25, 2022. The replay numbers are 888-203-1112 (U.S.) or +1 719-457-0820 (international), access code 1667821, PIN 3270.

Hologic will provide a live webcast of the call on the Company’s website at www.investors.hologic.com.

The call will be archived there for 30 days.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Senior Investor Relations Specialist
858-410-8904
paula.izidoro@hologic.com

Hologic, Inc.

NASDAQ:HOLX

Release Summary
HOLX to Announce Financial Results for the First Quarter of Fiscal 2022 on Wednesday, February 2, 2022
Release Versions

Contacts

Paula Izidoro
Senior Investor Relations Specialist
858-410-8904
paula.izidoro@hologic.com

More News From Hologic, Inc.

New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration

MARLBOROUGH, Mass.--(BUSINESS WIRE)--New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test...

New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA

MARLBOROUGH, Mass.--(BUSINESS WIRE)--New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA...

Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking...
Back to Newsroom